Oxford
Baltimore
27 similar offers
Looks like Vaccitech plc doesn’t have any active openings at the moment. Here’s a list of alternatives which you might find interesting.
Vaccitech plc
Scale-up
Product
The story
Our Mission: We discover and develop immunotherapeutics products and vaccines for the treatment and prevention of infectious diseases and cancer.
There are
11 – 50
employees in the company5M to 10M
Company annual revenueOffices
From March 2022 Vaccitech's UK headquarters will be moving to a state-of-the-art facility in the UK's leading science and innovation campus at Harwell. In Q3 we also plan to move our US operations from Baltimore to Montgomery County.
Stock options
Extra vacations
Remote work
Health insurance
Learn more about Vaccitech plc
Markets
Vaccitech is backed by leading investment institutions, including M&G, Tencent, Gilead Sciences, GV (formerly Google Ventures), Sequoia Capital China, Liontrust (formerly Neptune), Korea Investment Partners and Oxford Sciences Innovation.
At only five years old we already have a development portfolio of six products, a partnered product that is in commercial production that has seen more than 3 billion doses administered worldwide and an IPO behind us. We are a publicly-listed clinical stage biopharmaceutical company that spun out of the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centres in the world.
At only five years old we already have a development portfolio of six products, a partnered product that is in commercial production that has seen more than 3 billion doses administered worldwide and an IPO behind us. We are a publicly-listed clinical stage biopharmaceutical company that spun out of the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centres in the world.